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Membranous glomerulonephritis accounts for 20% of all cases of adult lupus nephritis \[[@B1]\]. Lupus membranous nephritis (MN) is relatively rare in children \[[@B2], [@B3]\]. Histologically, it is characterized by subepithelial immune deposits along the peripheral capillary loops leading to uniform thickening of the glomerular capillary wall. Immunofluorescence shows subepithelial and often concomitant mesangial immune deposits. MN presents with various clinical signs ranging from nephrotic syndrome (NS) to asymptomatic proteinuria. In most cases, proteinuria is nonselective and associated with microscopic hematuria. Hypertension is present in a small subset of patients \[[@B1]\].

In children, MN is responsible of 5% of cases of primary NS, while in adults it is considered a main cause of NS \[[@B1], [@B2]\]. Histologically, MN is characterized by the uniform thickening of the glomerular capillary wall on light microscopy. The latter thickening is associated with subepithelial immune complex deposits that appear as granular deposits of immunoglobulin G on immunofluorescence. Recently two target antigens have been discovered, neutral endopeptidase \[[@B4]\] and type-M phospholipase A2 receptor (PLA2R) \[[@B5]\]. PLA2R is the first autoantigen identified in idiopathic membranous nephropathy in adults. This provides new tools for monitoring disease activity and should help designing new antigen-driven therapeutic strategies in the future.

MN can manifest in a clinical setting of lupus nephritis, hepatitis B, Epstein Barr virus and others \[[@B1], [@B6], [@B7], [@B8]\]. Other rare causes have been described including C4 complement deficiency and antitubular basement membrane antibodies \[[@B9]\].

The treatment algorithm for managing MN in adults relies on assessing the prognostic factors at illness onset and trying to achieve a balance between the probability of renal failure and the risk of immunosuppression. Since MN is rare in the pediatric age group, no standardized approach to therapy in children has been identified \[[@B2], [@B7]\]. Patients with lupus MN present with proteinuria and hematuria up to NS. Patients are frequently treated with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), and often with a low-salt diet or thiazide diuretics. Other protocols have been proposed including short steroid therapy, more potent immunosuppressive drugs like cyclophosphamide, mycophenolic acid, calcineurin inhibitors, and B-cell depleting agents, but controlled studies are rare \[[@B10], [@B11], [@B12], [@B13], [@B14], [@B15], [@B16], [@B17]\] despite existing guidelines from the KDIGO \[[@B18]\], ERA/EDTA \[[@B19]\] and ACR \[[@B20]\]. Specific pediatric recommendations do not exist.

The use of immunoadsorption has been considered in several autoimmune diseases, but still studies are lacking in the pediatric and adolescent age group.
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We report the case of an 11-year-old previously healthy girl (36 kg, 151 cm) who presented to the emergency room for nephrotic proteinuria and microscopic hematuria found on routine dipstick examination. The patient was afebrile, without edemas. Initially analysis showed a serum creatinine of 42 μmol/l, with a total serum protein of 62 g/l. Three weeks later, the patient had palpebral edema, initially considered as an allergic manifestation and treated by antihistamine medication for 2 weeks. Therefore, total serum protein levels decreased to 46 g/l and albumin was 11 g/l, with a proteinuria of 12 g/l. Vital signs were normal with a blood pressure of 123/76 mm Hg.

The patient was initially treated as idiopathic NS with daily oral prednisone therapy (60 mg/m^2^) for 1 month. Immunological investigations showed elevated antinuclear antibodies (\>1/640), positive anti-Smith antibodies, and positive anti-ribonuclear antibodies, with a normal complement including C3 (1,090 mg/l), C4 (321 mg/l), and CH50 (145%). Serology for hepatitis B, C and HIV returned negative. Renal ultrasound showed well-differentiated kidneys of normal size.

Kidney biopsy revealed histological lesions and immunofluorescence deposits compatible with membranous lupus nephritis. No vascular or tubulointerstitial fibrosis was found. The patient was started on ACEi (enalapril 20 mg once daily), ARB (losartan 50 mg once daily), mycophenolic acid (540 mg twice daily), and hydroxychloroquine (200 mg daily).

Five months later, nephrotic proteinuria (8 g/l) and hypoalbuminemia (11 g/l) persisted. Therefore, we decided to perform ten sessions of daily immunoadsorption (TheraSorb Ig flex adsorbers, LIFE 18; Miltenyi Biotec GmbH, Teterow, Germany). Proteinuria decreased significantly over these ten sessions from 8 to 0.12 g/l after session 8 (fig. [1](#F1){ref-type="fig"}). After the tenth immunoadsorption session, the patient received a first rituximab (RTX) infusion (375 mg/m^2^). The initial CD19 and CD20 levels were 28% and became 0% at 6 days after the RTX injection. The patient was maintained on ACEi and thiazide diuretics associated with hydroxychloroquine and mycophenolic acid. Three RTX reinjections were performed at 375 mg/m^2^ after 3, 5 and 7 months, respectively, when CD19-positive cells recovered in peripheral blood (13, 12 and 17%, respectively).

Despite complete B-cell recovery and positive anti-dsDNA-Ab, the patient remained in complete remission 24 months after the initial diagnosis; she has negative proteinuria and a normal serum creatinine of 37 μmol/l. During the whole follow-up period, the patient was maintained on ACEi, mycophenolic acid and hydroxychloroquine.
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Lupus nephritis remains the most common severe manifestation of systemic lupus erythematosus characterized by the presence of autoantibodies (Abs) that are believed to play a central role in its pathogenesis. Among more than 100 Abs reported in systemic lupus erythematosus, only a few display a direct glomerular binding capacity. Such antiglomerular Abs are detected at the onset of the disease generally before the detection of antinuclear Abs. Antiglomerular Abs encompass anti-α-actinin, anti-laminin-1, antifibronectin, antimyosin and anticollagen Abs.

Extracorporeal immunoadsorption is a method to remove such circulating antibodies mainly, thus potentially reducing the antibody-kidney deposition and proteinuria \[[@B21]\]. Data on membranous lupus nephritis in children are rare. Long-term prognosis in class 5 lupus nephritis patients depends on treatment response \[[@B22], [@B23]\]. Corticosteroid treatment seems to be of relatively low efficiency and its indication in pure class 5 lupus nephritis is strongly questioned today as long as there is no proliferative lesion associated to MN.

Our patient had initially normal complement C3 and C4 levels, but anti-nuclear Abs were initially present and anti-dsDNA-Abs were initially negative and were positive 1 month later. They remained positive during the whole B-cell depletion period. However, proteinuria changed from nephrotic range to negative after ten daily immunoadsorption sessions.

If specific lupus antibodies are believed to be involved in the pathomechanism of proteinuria in membranous lupus nephritis, it is surprising that proteinuria became rapidly negative after introduction of immunoadsorption while anti-ds-DNA Abs were still present during and after immunoadsorption and during B-cell depletion. Therefore, one may hypothesize that other Abs not related to anti-DNA might have played a role in disease activity.

In conclusion, it seems that immunoadsorption can help to reduce proteinuria safely in patients with membranous lupus nephritis and persistent nephrotic range proteinuria despite several months of ACEi/ARB, mycophenolic acid and hydroxychloroquine treatment. Negative proteinuria at the time of RTX injection may increase RTX bioavailability.
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